Interferon beta for secondary progressive multiple sclerosis (Q24203879)

1

0 references

Carlo Di Pietrantonj

3

0 references

author name string

Laura Vacchi

2

0 references

George Ebers

4

0 references

Marco Rovaris

5

0 references

Sten Fredrikson

Cochrane Database of Systematic Reviews

6

0 references

language of work or name

English

0 references

publication date

18 January 2012

0 references

published in

0 references

volume

1

0 references

page(s)

CD005181

0 references

cites work

Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Increased disability and MRI lesions after discontinuation of IFN-beta-1a in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Once-weekly 22microg subcutaneous IFN-beta-1a in secondary progressive MS: a 3-year follow-up study on brain MRI measurements and serum MMP-9 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Change in clinician-assessed measures of multiple sclerosis and subject-reported quality of life: results from the IMPACT study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Interferon beta1a and depression in secondary progressive MS: data from the SPECTRIMS Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Interferon beta therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

The precision of T1 hypointense lesion volume quantification in multiple sclerosis treatment trials: a multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

A reassessment of the plateauing relationship between T2 lesion load and disability in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Safety and tolerability of a 'refrigeration-free' formulation of interferon beta-1b--results of a double-blind, multicentre, comparative study in patients with relapsing-remitting or secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Effects of donepezil on memory and cognition in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Interferon beta in secondary progressive multiple sclerosis : daily clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Natural history of multiple sclerosis: a unifying concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Memory decline evolves independently of disease activity in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Disability as an outcome in MS clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Comparative study of mitoxantrone efficacy profile in patients with relapsing—remitting and secondary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Interferons in relapsing remitting multiple sclerosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

The relation between inflammation and neurodegeneration in multiple sclerosis brains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Mechanisms underlying inflammation in neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Axonal and neuronal pathology in multiple sclerosis: what have we learnt from animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Effect of relapses on development of residual deficit in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Interferon therapy in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of the comparative trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Interferon in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Disability progression in multiple sclerosis is slower than previously reported.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Impact of multiple sclerosis relapses on progression diminishes with time

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Cognitive dysfunction in primary progressive multiple sclerosis: a neuropsychological and MRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

The natural history of secondary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

New natural history of interferon-β-treated relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

7 January 2021

[Interferon beta-1b for treatment of secondary chronic progressive multiple sclerosis]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

7 January 2021

Interferon beta treatment for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

7 January 2021

Interferon beta treatment for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

7 January 2021

Relapses and progression of disability in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

7 January 2021

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

7 January 2021

The natural history of multiple sclerosis: a geographically based study: 8: familial multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

7 January 2021

Efficacy of EMLA cream to reduce fear and pain associated with interferon beta-1a injection in patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

7 January 2021

Natural interferon-beta treatment of relapsing-remitting and secondary-progressive multiple sclerosis patients. A two-year study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

7 January 2021

Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

7 January 2021

Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

7 January 2021

Interferon beta-1b treatment does not induce autoantibodies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

7 January 2021

Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

7 January 2021

Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

7 January 2021

The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

7 January 2021

Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005181.PUB3

7 January 2021